Myriad Genetics has appointed Bernard Tobin as president of Crescendo Bioscience. Tobin joins Myriad from Amgen, where over the past seven years he has held various leadership roles, including executive director of national accounts, general manager of theNetherlandsandBrazil, as well as global head of commercial excellence. Before Amgen, Tobin had worked at Eli Lilly and Co.
Tobin will take over for William Hagstrom and report to Myriad CEO Peter Meldrum. Hagstrom has decided to leave Crescendo to pursue startup and social venture opportunities. He will stay with the company until Jan. 2, 2015, and Tobin's appointment will be effective as of Jan. 5.